Fusion protein technologies for biopharmaceuticals : applications and challenges / edited by Stefan R. Schmidt.
Material type:
TextPublication details: Hoboken, New Jersey : John Wiley & Sons, ©2013.Description: 1 online resourceContent type: - text
- computer
- online resource
- 9781118354582
- 1118354583
- 9781118354575
- 1118354575
- 9781118354568
- 1118354567
- 9781118354599
- 1118354591
- 9781299241954
- 1299241956
- Biopharmaceutics
- Pharmaceutical biotechnology
- Drug carriers
- Immunotoxins -- Therapeutic use
- Protein engineering
- Recombinant fusion proteins -- Therapeutic use
- MEDICAL -- Pharmacology
- Biopharmaceutics
- Pharmaceutical biotechnology
- Recombinant Fusion Proteins -- therapeutic use
- Drug Carriers
- Immunotoxins -- pharmacokinetics
- Immunotoxins -- therapeutic use
- Protein Engineering
- Recombinant Fusion Proteins -- pharmacokinetics
- 615.7 23
- RM301.4 .F87 2013
- QU 450
Includes bibliographical references and index.
Print version record and CIP data provided by publisher.
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
There are no comments on this title.